Zurich Cantonal Bank
DYN icon

Zurich Cantonal Bank’s Dyne Therapeutics DYN Stock Holding History

Zurich Cantonal Bank’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.31M Buy
58,947
+6,795
+13% +$126K ﹤0.01% 1381
2026
Q1 		$946K Buy
+52,152
New +$899K ﹤0.01% 1465
2025
Q4 		– Sell
-33,314
Closed -$631K – 2851
2025
Q3 		$421K Buy
33,314
+14,067
+73% +$160K ﹤0.01% 1837
2025
Q2 		$183K Hold
19,247
– – ﹤0.01% 2172
2025
Q1 		$201K Buy
19,247
+3,496
+22% +$50K ﹤0.01% 2099
2024
Q4 		$371K Buy
15,751
+6,418
+69% +$190K ﹤0.01% 1810
2024
Q3 		$335K Sell
9,333
-21
-0.2% -$836 ﹤0.01% 1814
2024
Q2 		$330K Sell
9,354
-21
-0.2% -$610 ﹤0.01% 1769
2024
Q1 		$266K Buy
9,375
+996
+12% +$22.5K ﹤0.01% 1893
2023
Q4 		$111K Hold
8,379
– – ﹤0.01% 2395
2023
Q3 		$75.1K Buy
8,379
+3,092
+58% +$33.3K ﹤0.01% 2483
2023
Q2 		$59.5K Buy
+5,287
New +$62.4K ﹤0.01% 2553

Other funds holding DYN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Zurich Cantonal Bank's DYN Position: Q2 2026 in Review

Zurich Cantonal Bank increased its Dyne Therapeutics (DYN) stake by 13% in Q2 2026, buying an estimated $126K and bringing the position to 58,947 shares worth $1.31M. The position accounts for ﹤0.01% of the portfolio, ranked #1381.

Zurich Cantonal Bank first reported a position in DYN in Q2 2023 and has held it in 12 quarters since. 246 funds tracked by Wall St. Rank hold DYN as of Q2 2026.

  • Zurich Cantonal Bank held 58,947 shares of Dyne Therapeutics worth $1.31M as of Q2 2026.
  • Zurich Cantonal Bank bought 6,795 Dyne Therapeutics shares in Q2 2026, an estimated $126K.
  • Dyne Therapeutics made up ﹤0.01% of Zurich Cantonal Bank's portfolio in Q2 2026, its #1381 holding.
  • Zurich Cantonal Bank first reported a position in Dyne Therapeutics in Q2 2023 and has held it in 12 quarters since.
  • 246 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q2 2026.

Based on Zurich Cantonal Bank's 13F filing for Q2 2026, filed 12 Aug 2026.